Aliases & Classifications for Splenomegaly

Summaries for Splenomegaly

MalaCards based summary : Splenomegaly is related to polycythemia vera and budd-chiari syndrome. An important gene associated with Splenomegaly is JAK2 (Janus Kinase 2), and among its related pathways/superpathways are Jak-STAT signaling pathway (KEGG) and Jak-Stat Signaling Pathway (sino). The drugs Praziquantel and Zinc have been mentioned in the context of this disorder. Affiliated tissues include spleen, bone and liver, and related phenotypes are hematopoietic system and homeostasis/metabolism

Wikipedia : 72 Splenomegaly is an enlargement of the spleen. The spleen usually lies in the left upper quadrant (LUQ)... more...

Related Diseases for Splenomegaly

Diseases related to Splenomegaly via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 298)
# Related Disease Score Top Affiliating Genes
1 polycythemia vera 31.4 EPO JAK2 MPL
2 budd-chiari syndrome 31.2 JAK2 MPL
3 myelofibrosis 30.4 EPO IFNA2 JAK2 MPL
4 essential thrombocythemia 30.3 EPO IFNA2 JAK2 MPL
5 pancytopenia 30.0 EPO MPL
6 leukemia, chronic myeloid 29.8 EPO IFNA2 JAK2 MPL SETBP1
7 retinitis pigmentosa and erythrocytic microcytosis 29.8 EPO JAK2
8 chronic myelomonocytic leukemia 29.8 JAK2 SETBP1
9 myeloproliferative neoplasm 29.7 JAK2 MPL
10 polycythemia 29.5 EPO JAK2 MPL
11 thrombocytosis 29.5 EPO JAK2 MPL
12 systemic mastocytosis 29.3 IFNA2 JAK2
13 leukemia, acute myeloid 29.2 JAK2 MPL SETBP1
14 congenital hemolytic anemia 29.1 EPO SPTB
15 refractory anemia 29.1 EPO JAK2 MPL
16 myelodysplastic syndrome 28.8 EPO JAK2 MPL SETBP1
17 splenomegaly, cytopenia, and vision loss 12.2
18 chronic congestive splenomegaly 12.2
19 myeloid splenomegaly 12.1
20 splenomegaly syndrome with splenic germinal center hypoplasia and reduced circulating t helper cells 11.9
21 sea-blue histiocyte disease 11.7
22 felty syndrome 11.6
23 hypersplenism 11.4
24 gaucher's disease 11.3
25 banti's syndrome 11.2
26 b-cell expansion with nfkb and t-cell anergy 11.2
27 zimmermann-laband syndrome 1 11.2
28 hereditary spherocytosis 11.2
29 gray platelet syndrome 11.2
30 prolidase deficiency 11.2
31 hairy cell leukemia 11.0
32 wandering spleen 11.0
33 persistent polyclonal b-cell lymphocytosis 11.0
34 autoimmune lymphoproliferative syndrome 11.0
35 pdgfrb-associated chronic eosinophilic leukemia 11.0
36 anemia, autoimmune hemolytic 11.0
37 common variable immunodeficiency 11.0
38 dehydrated hereditary stomatocytosis 1 with or without pseudohyperkalemia and/or perinatal edema 10.9
39 caspase 8 deficiency 10.9
40 tang hsi ryu syndrome 10.9
41 autoinflammation with infantile enterocolitis 10.8
42 spherocytosis, type 2 10.8
43 lymphoproliferative syndrome, x-linked, 2 10.8
44 immunodeficiency 52 10.8
45 thrombocytopenia with beta-thalassemia, x-linked 10.8
46 typhoid fever 10.7
47 spherocytosis, type 1 10.7
48 congenital toxoplasmosis 10.7
49 overhydrated hereditary stomatocytosis 10.7
50 hemophagocytic lymphohistiocytosis, familial, 4 10.7

Graphical network of the top 20 diseases related to Splenomegaly:



Diseases related to Splenomegaly

Symptoms & Phenotypes for Splenomegaly

MGI Mouse Phenotypes related to Splenomegaly:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.8 APOE EPO GBA JAK2 MPL SPTB
2 homeostasis/metabolism MP:0005376 9.8 APOE EPO GBA JAK2 MPL SETBP1
3 immune system MP:0005387 9.63 APOE EPO GBA JAK2 MPL SPTB
4 liver/biliary system MP:0005370 9.35 SPTB APOE EPO GBA JAK2
5 mortality/aging MP:0010768 9.17 APOE EPO GBA JAK2 MPL SETBP1

Drugs & Therapeutics for Splenomegaly

Drugs for Splenomegaly (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 110)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Praziquantel Approved, Investigational, Vet_approved Phase 4 55268-74-1 4891
2
Zinc Approved, Investigational Phase 4 7440-66-6 32051 23994
3
Lactitol Investigational Phase 4 585-86-4 3871
4 Anthelmintics Phase 4,Phase 3
5 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
6 Antiparasitic Agents Phase 4,Phase 3,Phase 1
7
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
8
Fludarabine Approved Phase 3,Phase 2,Phase 1 21679-14-1, 75607-67-9 30751
9
rituximab Approved Phase 3,Phase 2,Phase 1 174722-31-7 10201696
10
Prednisone Approved, Vet_approved Phase 3,Phase 2 53-03-2 5865
11
Hydroxyurea Approved Phase 3,Phase 2 127-07-1 3657
12
Vidarabine Approved, Investigational Phase 3 24356-66-9 21704 32326
13
Cytarabine Approved, Investigational Phase 3 147-94-4 6253
14
Melphalan Approved Phase 3 148-82-3 460612 4053
15
Danazol Approved Phase 3 17230-88-5 28417
16 Alkylating Agents Phase 3,Phase 2,Phase 1
17 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1,Early Phase 1
18 Immunoglobulins Phase 3,Phase 2,Phase 1,Early Phase 1
19 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
20 Antimetabolites Phase 3,Phase 2,Phase 1
21 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
22 Antibodies Phase 3,Phase 2,Phase 1,Early Phase 1
23 Antirheumatic Agents Phase 3,Phase 2,Phase 1
24 glucocorticoids Phase 3,Phase 2
25 Hormone Antagonists Phase 3,Phase 2
26 Hormones Phase 3,Phase 2
27 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2
28 Antimalarials Phase 3,Phase 1
29 Anti-Inflammatory Agents Phase 3,Phase 2
30 Antineoplastic Agents, Hormonal Phase 3,Phase 2
31 Antiprotozoal Agents Phase 3,Phase 1
32 Antiviral Agents Phase 3,Phase 1
33 interferons Phase 3,Phase 2
34 Pharmaceutical Solutions Phase 2, Phase 3
35 Krestin Phase 3
36 Vidarabine Phosphate Phase 3
37 6-Mercaptopurine Phase 3
38
belimumab Approved Phase 2 356547-88-1 5957 10451420
39
Valproic Acid Approved, Investigational Phase 1, Phase 2 99-66-1 3121
40
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
41
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
42
alemtuzumab Approved, Investigational Phase 2 216503-57-0
43
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
44 Pomalidomide Approved Phase 2 19171-19-8
45
Busulfan Approved, Investigational Phase 2 55-98-1 2478
46
Anagrelide Approved Phase 2 68475-42-3 2182
47
Trametinib Approved Phase 2 871700-17-3 11707110
48
Obinutuzumab Approved, Investigational Phase 1, Phase 2 949142-50-1
49
Bevacizumab Approved, Investigational Phase 2 216974-75-3
50
Citric Acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311

Interventional clinical trials:

(show top 50) (show all 72)

# Name Status NCT ID Phase Drugs
1 Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF) Completed NCT01558739 Phase 4 INC424
2 Evaluation of Praziquantel Dosage for Treatment of Schistosomiasis in Brazil Completed NCT00403611 Phase 4 Praziquantel 60 mg/kg;Praziquantel 40 mg/kg
3 CINC424A2X01B Rollover Protocol Recruiting NCT02386800 Phase 4 Ruxolitinib
4 Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis Completed NCT01437787 Phase 3 SAR302503;Placebo
5 Phase III Study Investigating the Efficacy and Safety of Ruxolitinib in Early Myelofibrosis Patients With High Molecular Risk Mutations. Completed NCT02598297 Phase 3 Ruxolitinib;Ruxolitinib Placebo
6 Efficacy, Safety, Pharmacodynamic, and Pharmacokinetics Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency Recruiting NCT02004691 Phase 2, Phase 3 placebo (saline);GZ402665
7 Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency Recruiting NCT03113760 Phase 3 Tadekinig alfa;Placebo
8 Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Active, not recruiting NCT02048813 Phase 3 Cyclophosphamide;Fludarabine Phosphate;Ibrutinib
9 Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia Terminated NCT02055781 Phase 3 Pacritinib;Best Available Therapy
10 Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis Terminated NCT01773187 Phase 3 Pacritinib;Best Available Therapy
11 Prednisone Plus Chloroquine for the Treatment of Hyper-reactive Malarial Splenomegaly Withdrawn NCT01785979 Phase 3 prednisone induction - chloroquine;Chloroquine
12 CEP-701 (Lestaurtinib) in Myelofibrosis Unknown status NCT00668421 Phase 1, Phase 2 CEP-701 (Lestaurtinib)
13 A Study of Belimumab in Treating Symptomatic Waldenstroms Macroglobulinaemia Unknown status NCT01142011 Phase 2 Belimumab
14 Phase 2 Study in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly Completed NCT01692366 Phase 2 SAR302503
15 Phase 2 Study of SAR302503 in Patients With Myelofibrosis Completed NCT01420770 Phase 2 SAR302503
16 Study of Efficacy and Safety of INC424 in Regularly Transfused Patients With Thalassemia. Completed NCT02049450 Phase 2 ruxolitinib
17 Thalidomide, Prednisone, and Cyclophosphamide in Treating Patients With Myelofibrosis and Myeloid Metaplasia Completed NCT00445900 Phase 2 cyclophosphamide;prednisone;thalidomide
18 Valproic Acid (Depakote[Registered Trademark]) to Treat Autoimmune Lymphoproliferative Syndrome (ALPS) Completed NCT00605657 Phase 1, Phase 2 Valproic Acid
19 Velcade (Bortezomib - PS341) in the Treatment of Patients Over 18 Years With Ph+ Leukemia Completed NCT00511069 Phase 2 Bortezomib
20 Imatinib Mesylate in Treating Patients With Myelofibrosis Completed NCT00039416 Phase 2 imatinib mesylate
21 Pomalidomide in Patients With Myeloproliferative Neoplasms in Fibrotic Stage Completed NCT00949364 Phase 2 Pomalidomide
22 Treatment of Polycythemia Vera With Gleevec Completed NCT01120821 Phase 2 Gleevec
23 Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis Completed NCT00586651 Phase 2 lestaurtinib
24 HuMax-CD20 in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Failing Fludarabine and Alemtuzumab Completed NCT00349349 Phase 2 ofatumumab
25 The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia Recruiting NCT02577926 Phase 2 Ruxolitinib;BAT
26 Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia Recruiting NCT02730884 Phase 2 Rigosertib
27 A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Participants With Hydroxyurea-Resistant/Intolerant Polycythemia Vera Recruiting NCT03287245 Phase 2 Idasanutlin
28 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib Recruiting NCT03165734 Phase 2 Pacritinib
29 Ruxolitinib (INCB018424) in Subjects With Primary Myelofibrosis, Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis Recruiting NCT01348490 Phase 2 Ruxolitinib (INCB018424)
30 Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia Recruiting NCT03190915 Phase 2 Trametinib
31 Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma Recruiting NCT03010358 Phase 1, Phase 2 Entospletinib
32 A Study Evaluating Tolerability and Efficacy of Navitoclax in Combination With Ruxolitinib in Subjects With Myelofibrosis Recruiting NCT03222609 Phase 2 Navitoclax
33 Imetelstat Sodium in Treating Patients With Primary or Secondary Myelofibrosis Active, not recruiting NCT01731951 Phase 2 Imetelstat
34 Trial of Erlotinib in Patients With JAK-2 V617F Positive Polycythemia Vera Terminated NCT01038856 Phase 2 Erlotinib
35 Phase II Study of Bevacizumab (Avastin®) in Myelofibrosis Terminated NCT00667277 Phase 2 bevacizumab (Avastin)
36 Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia Terminated NCT01998828 Phase 2 Momelotinib
37 A Phase Ib Study of ISF35 in Combination With Chemotherapy (FCR) in Subjects With Relapsed, Refractory, and/or 17p- CLL Unknown status NCT00772486 Phase 1
38 Pilot and Feasibility Trial of Plerixafor for Hematopoietic Stem Cell (HSC) Mobilization in Patients With Sickle Cell Disease Pilot and Feasibility Trial of Plerixafor for Hematopoietic Stem Cell (HSC) Mobilization in Patients With Sickle Cell Disease Completed NCT02989701 Phase 1 Plerixafor
39 A Phase I Trial of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35) Completed NCT00779883 Phase 1
40 A Phase I Extension Trial of Repeated Infusions of ISF35 Completed NCT00783588 Phase 1
41 Pyrimethamine and Sulfadoxine for Treatment of Autoimmune Lymphoproliferative Syndrome Completed NCT00013689 Phase 1 Fansidar (pyrimethamine and sulfadoxine)
42 Pyrimethamine to Treat Autoimmune Lymphoproliferative Syndrome Completed NCT00065390 Phase 1 Pyrimethamine
43 Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia Recruiting NCT02948283 Phase 1 Metformin Hydrochloride;Ritonavir
44 Hemolysis in Patients With Hereditary Spherocytosis (HS) Unknown status NCT01201174
45 Microwave Ablation and Partial Splenic Embolization in the Management of Hypersplenism Unknown status NCT02261584
46 Study of the Impact of Hypersplenism and Splenectomy on Hepatocarcinogenesis in Patients With Posthepatitic Cirrhosis Unknown status NCT01201655
47 Novel Association of Cholesterol Ester Storage Disease Due to Lysosomal Acid Lipase Deficiency and Non-Alcoholic Fatty Liver Disease: A Prospective Clinical Study Unknown status NCT01791452
48 International Registry for Severe Chronic Neutropenia Unknown status NCT00004342
49 Relationships Between Mean Plasma Glucose and HbA1c in Cirrhotic Patients With Hepatogenous Diabetes Unknown status NCT02325622
50 Estimation of Spleen by Residents With VScan Completed NCT01907932

Search NIH Clinical Center for Splenomegaly

Genetic Tests for Splenomegaly

Genetic tests related to Splenomegaly:

# Genetic test Affiliating Genes
1 Splenomegaly 28

Anatomical Context for Splenomegaly

MalaCards organs/tissues related to Splenomegaly:

38
Spleen, Bone, Liver, Bone Marrow, B Cells, Myeloid, T Cells

Publications for Splenomegaly

Articles related to Splenomegaly:

(show top 50) (show all 706)
# Title Authors Year
1
Determination of splenomegaly by coronal oblique length on CT. ( 29143912 )
2018
2
Ruxolitinib is effective and safe in Japanese patients with hydroxyurea-resistant or hydroxyurea-intolerant polycythemia vera with splenomegaly. ( 28956263 )
2018
3
Hsp90 inhibition disrupts JAK-STAT signaling and leads to reductions in splenomegaly in patients with myeloproliferative neoplasms. ( 29051283 )
2018
4
Short-term administration of JAK2 inhibitors reduces splenomegaly in mouse models of I^-thalassemia intermedia and major. ( 29097498 )
2018
5
Robust Multicontrast MRI Spleen Segmentation for Splenomegaly Using Multi-Atlas Segmentation. ( 29364118 )
2018
6
Splenomegaly: Pathophysiological bases and therapeutic options. ( 29191734 )
2018
7
Praziquantel Targets M1 Macrophages and Ameliorates Splenomegaly in Chronic Schistosomiasis. ( 29061758 )
2018
8
Airway management of a paediatric patient with temporomandibular joint ankylosis with extra hepatic portal vein obstruction, splenomegaly, hypersplenism, and obstructive sleep apnoea for shunt surgery: A unique challenge. ( 29217866 )
2017
9
Cystic splenomegaly: ectopic adenocarcinoma of unknown primary. ( 28663224 )
2017
10
<sup>18</sup> F-Fluorodeoxyglucose positron emission tomography-computed tomography imaging in HIV-infected patients with lymphadenopathy, with or without fever and/or splenomegaly. ( 29198183 )
2017
11
Turf wars: exploring splenomegaly in sickle cell disease in malaria-endemic regions. ( 28493472 )
2017
12
Patients with Fever of Unknown Origin and Splenomegaly: Diagnostic Value of Splenectomy and Preoperative Risk Factors Suggestive of Underlying Lymphomas. ( 28586777 )
2017
13
Multi-atlas Segmentation Enables Robust Multi-contrast MRI Spleen Segmentation for Splenomegaly. ( 28649156 )
2017
14
Splenomegaly ( 28613657 )
2017
15
Steroid-Refractory Autoimmune Hemolytic Anemia with Massive Splenomegaly. ( 28389309 )
2017
16
A Case of Nephrotic Syndrome with Thrombocytopenia, Lymphadenopathy, Systemic Inflammation, and Splenomegaly. ( 29269660 )
2017
17
Fetal Splenomegaly: A Review. ( 29194292 )
2017
18
Hairy cell leukemia: a case report of atypical presentation without splenomegaly. ( 28698853 )
2017
19
Laparoscopic Splenectomy for Massive Splenomegaly: Does Size Matter? ( 28799827 )
2017
20
Multifactorial Splenomegaly. ( 29334440 )
2017
21
Splenomegaly - Diagnostic validity, work-up, and underlying causes. ( 29135986 )
2017
22
Splenomegaly in the returning traveller: a diagnostic workup. ( 28077481 )
2017
23
B-cell activating factor deficiency suppresses splenomegaly during Leishmania donovani infection. ( 28583852 )
2017
24
Familial spontaneous splenic rupture in a patient with idiopathic splenomegaly-report of a case. ( 28702168 )
2017
25
Single port laparoscopic splenectomy for wandering spleen with splenomegaly in a patient with Wolf-Hirschhorn syndrome. ( 28281478 )
2017
26
A case of splenomegaly in CBL syndrome. ( 28414188 )
2017
27
Emergency splenectomy for trauma in the setting of splenomegaly, axillary lymphadenopathy, and incidental B-cell chronic lymphocytic leukemia: A case report. ( 28686924 )
2017
28
Splenomegaly and the JAK2 V617F mutation. ( 27727073 )
2017
29
Comparing Physical Examination With Sonographic Versions of the Same Examination Techniques for Splenomegaly. ( 29219201 )
2017
30
Bone marrow fibrosis in chronic myelomonocytic leukemia is associated with increased megakaryopoiesis, splenomegaly and with a shorter median time to disease progression. ( 29262560 )
2017
31
Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study. ( 27916398 )
2017
32
Splenomegaly, myeloid lineage expansion and increased osteoclastogenesis in osteogenesis imperfecta murine. ( 28600151 )
2017
33
Unusual case of splenomegaly and pancytopenia in a returned traveller. ( 29105271 )
2017
34
Fever of unknown origin and splenomegaly: A case report of blood culture negative endocarditis. ( 29390335 )
2017
35
Filarial huge splenomegaly dramatically regressed by anti-filarial medication: A rare clinical scenario. ( 28944146 )
2017
36
Massive splenomegaly due to concurrent primary Epstein-Barr virus and cytomegalovirus infection in a patient on adalimumab. ( 28864556 )
2017
37
Efficacy of bendamustine on thrombocytopenia and hemolytic anemia secondary to CD5-positive B-cell lymphoma with massive splenomegaly in a patient with rheumatoid arthritis. ( 29181179 )
2017
38
Splenomegaly in small-breed dogs: 45 cases(2005-2011). ( 28467747 )
2017
39
Successful management of splenomegaly with ruxolitinib prior to allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia transformed from post-polycythemia vera myelofibrosis. ( 28781268 )
2017
40
Image Diagnosis: A Gastric Signet-Ring Adenocarcinoma of Type Linitis Plastica Mimicking Splenomegaly in a Patient with Chronic Lymphocytic Leukemia. ( 28609263 )
2017
41
Effect of gold nanoparticles on mice splenomegaly induced by schistosomiasis mansoni. ( 28855840 )
2017
42
Disseminated coccidioidomycosis with molluscum-like lesions, diffuse lymphadenopathy, and splenomegaly in an immunocompetent patient. ( 28769594 )
2017
43
The Best Single Measurement for Assessing Splenomegaly in Patients with Cirrhotic Liver Morphology. ( 28800952 )
2017
44
Identification and characterization of avian hepatitis E virus genotype 2 from chickens with hepatitis-splenomegaly syndrome in Korea. ( 27164843 )
2016
45
Non-FDG Avid Persistent Splenomegaly at Time of Transplantation Delays Neutrophil and Platelets Engraftment Without Affecting Survival in Patients with Lymphomas Undergoing Allogeneic Hematopoietic Cell Transplantation. ( 27660169 )
2016
46
Allogeneic Transplantation for Patients With Advanced Myelofibrosis: Splenomegaly and High Serum LDH are Adverse Risk Factors for Successful Engraftment. ( 27025789 )
2016
47
Hyper-reactive malarial splenomegaly : A case report. ( 27728705 )
2016
48
Correction: FOXP3+ Regulatory T Cells in Hepatic Fibrosis and Splenomegaly Caused by Schistosoma japonicum: The Spleen May Be a Major Source of Tregs in Subjects with Splenomegaly. ( 26849557 )
2016
49
FOXP3+ Regulatory T Cells in Hepatic Fibrosis and Splenomegaly Caused by Schistosoma japonicum: The Spleen May Be a Major Source of Tregs in Subjects with Splenomegaly. ( 26731721 )
2016
50
MPL mutations and palpable splenomegaly are independent risk factors for fibrotic progression in essential thrombocythemia. ( 27768091 )
2016

Variations for Splenomegaly

Expression for Splenomegaly

Search GEO for disease gene expression data for Splenomegaly.

Pathways for Splenomegaly

GO Terms for Splenomegaly

Biological processes related to Splenomegaly according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.54 IFNA2 JAK2 MPL
2 response to estrogen GO:0043627 9.48 EPO GBA
3 erythrocyte differentiation GO:0030218 9.46 EPO JAK2
4 negative regulation of MAP kinase activity GO:0043407 9.43 APOE GBA
5 response to testosterone GO:0033574 9.4 EPO GBA
6 response to dexamethasone GO:0071548 9.32 EPO GBA
7 regulation of protein metabolic process GO:0051246 9.26 APOE GBA
8 negative regulation of cellular protein metabolic process GO:0032269 9.16 APOE GBA
9 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.13 EPO IFNA2 JAK2
10 negative regulation of neuron death GO:1901215 8.8 APOE EPO GBA

Sources for Splenomegaly

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....